Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00875849
Recruitment Status : Completed
First Posted : April 3, 2009
Last Update Posted : November 21, 2014
Sponsor:
Information provided by (Responsible Party):
Centre Antoine Lacassagne

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy together with radiation therapy and cetuximab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well chemotherapy given together with radiation therapy and cetuximab works in treating patients with head and neck cancer.


Condition or disease Intervention/treatment Phase
Head and Neck Cancer Biological: cetuximab Drug: cisplatin Radiation: radiation therapy Phase 2

Detailed Description:

OBJECTIVES:

Primary

  • Evaluate disease-free survival at 2 years in patients with poor prognosis squamous cell carcinoma of the head and neck treated with chemoradiotherapy and cetuximab after complete surgical resection.

Secondary

  • Evaluate quality of life.
  • Evaluate tolerability.
  • Evaluate overall survival.
  • Analyze germinal polymorphisms.

OUTLINE: This is a multicenter study.

Patients receive cetuximab IV on day 1. Treatment with cetuximab repeats every week for up to 8 courses. Patients also receive cisplatin IV on day 8. Treatment with cisplatin repeats every 3 weeks for up to 3 courses. Patients undergo concurrent radiotherapy 5 times a week for 7 weeks beginning on day 8.

After completion of study treatment, patients are followed at 1 month and then every 3 months for 2 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection
Study Start Date : March 2008
Actual Primary Completion Date : February 2010
Actual Study Completion Date : December 2013


Arm Intervention/treatment
Experimental: Cetuximab Biological: cetuximab
Drug: cisplatin
Radiation: radiation therapy



Primary Outcome Measures :
  1. Disease-free survival at 2 years [ Time Frame: 2 YEARS ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
  • Must have undergone complete macroscopic resection
  • Presence of ≥ 1 of the following poor prognostic factors after complete resection:

    • Incomplete microscopic resection and N+
    • Complete microscopic resection and > 2 N+
    • Vascular and/or lymphatic embolism
    • At least 2 peripheral nerve invasions
    • Positive surgical margins and pT4 lesion
  • No metastases

PATIENT CHARACTERISTICS:

  • WHO performance status 0-2
  • ANC > 1,500/mm^3
  • Platelet count > 100,000/mm^3
  • Hemoglobin > 9 g/dL
  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • Serum creatinine < 1.25 times ULN and/or creatinine clearance > 55 mL/min
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No serious and disabling cardiac, renal, hepatic, or respiratory failure
  • No coronary artery disease or myocardial infarction within the past year
  • No uncontrolled cardiac arrhythmia
  • Other active and serious diseases allowed at discretion of the investigator
  • No known severe allergy to cisplatin, cetuximab, or any of their excipients
  • No other malignant disease diagnosed within the past 5 years except for basal cell carcinoma of the skin or in situ cervical cancer
  • No psychological, familial, social, or geographic situations that preclude clinical follow up

PRIOR CONCURRENT THERAPY:

  • No prior treatment (except surgery) for this cancer or another head and neck cancer
  • At least 3 months since prior treatment with an investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00875849


Locations
Layout table for location information
France
Centre Antoine Lacassagne
Nice, France, 06189
Sponsors and Collaborators
Centre Antoine Lacassagne
Investigators
Layout table for investigator information
Principal Investigator: Philippe Follana Centre Antoine Lacassagne

Layout table for additonal information
Responsible Party: Centre Antoine Lacassagne
ClinicalTrials.gov Identifier: NCT00875849     History of Changes
Other Study ID Numbers: CDR0000633474
CALACASS-AACER
MERCK-CALACASS-AACER
INCA-RECF0623
EUDRACT-2007-004384-22
First Posted: April 3, 2009    Key Record Dates
Last Update Posted: November 21, 2014
Last Verified: August 2012
Keywords provided by Centre Antoine Lacassagne:
recurrent squamous cell carcinoma of the hypopharynx
stage I squamous cell carcinoma of the hypopharynx
stage II squamous cell carcinoma of the hypopharynx
stage III squamous cell carcinoma of the hypopharynx
recurrent squamous cell carcinoma of the larynx
stage I squamous cell carcinoma of the larynx
stage II squamous cell carcinoma of the larynx
stage III squamous cell carcinoma of the larynx
stage I squamous cell carcinoma of the lip and oral cavity
stage II squamous cell carcinoma of the lip and oral cavity
stage III squamous cell carcinoma of the lip and oral cavity
recurrent squamous cell carcinoma of the lip and oral cavity
recurrent squamous cell carcinoma of the oropharynx
stage I squamous cell carcinoma of the oropharynx
stage II squamous cell carcinoma of the oropharynx
stage III squamous cell carcinoma of the oropharynx
tongue cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site
Cetuximab
Antineoplastic Agents
Antineoplastic Agents, Immunological